7.58
-0.73(-8.78%)
Currency In USD
| Previous Close | 8.31 |
| Open | 8.44 |
| Day High | 8.52 |
| Day Low | 7.52 |
| 52-Week High | 13.93 |
| 52-Week Low | 2.86 |
| Volume | 1.47M |
| Average Volume | 730,667 |
| Market Cap | 520.25M |
| PE | -3.85 |
| EPS | -1.97 |
| Moving Average 50 Days | 5.13 |
| Moving Average 200 Days | 5.35 |
| Change | -0.73 |
If you invested $1000 in Olema Pharmaceuticals, Inc. (OLMA) since IPO date, it would be worth $154.69 as of September 08, 2025 at a share price of $7.58. Whereas If you bought $1000 worth of Olema Pharmaceuticals, Inc. (OLMA) shares 3 years ago, it would be worth $1,714.93 as of September 08, 2025 at a share price of $7.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
GlobeNewswire Inc.
Sep 02, 2025 11:00 AM GMT
Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting SAN FR
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am–12:00pm
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
GlobeNewswire Inc.
Apr 25, 2025 5:00 PM GMT
Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancerPatient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy a